Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks immunotherapy safety in elderly cancer patients

NCT ID NCT03673332

Symptom relief Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-being using questionnaires. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Oct 2019

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients eligible to start a treatment including immune checkpoint inhibitors (Nivolumab, Ipilimumab, Pembrolizumab, and so on…) * Diagnosis of advanced or metastatic melanoma or NSCLC (All treatment lines will be allowed) * Age ≥ 70 years * Having personally signed and dated informed consent * Patient affiliated to the ''National security'' regimen or beneficiary of this regimen Exclusion Criteria: * Immune checkpoint inhibitor therapy initiated before study enrolment * Concomitant participation in other investigational clinical trials involving an immune checkpoint inhibitor * Immune checkpoint inhibitor treatment in a context of other solid tumours * Immune checkpoint inhibitor treatment in a context of haematological malignancies * Being unable or unwilling to comply with the requirements of the protocol, as assessed by the investigator * Patient in urgency situation, adult under legal protection, or unable to give his consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced or metastatic melanoma Advanced or metastatic NSCLC

Contacts and locations

Locations

  • Assistance Publique des Hôpitaux de Marseille

    Marseille, Bouches Du Rhône, 13385, France

  • CENTRE Francois Baclesse

    Caen, France

  • Centre Georges François Leclerc

    Dijon, 21079, France

  • IUCT-Oncopole Institut Claudius Rigaud

    Toulouse, France

  • Institut BERGONIE

    Bordeaux, France

  • Institut Curie

    Paris, France

  • Institut De Cancérologie de l'Ouest

    Saint-Herblain, France

  • Institut Du Cancer de Montpellier

    Montpellier, 34298, France

  • Institut Paoli-Calmettes

    Marseille, Bouches-du Rhône, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.